Comedonecrosis is an unfavorable marker in node-negative invasive breast carcinoma

Pathology International

Volumn 53, Issue 8, 2003, Pages 501-506

  Yagata, Hiroshi ^a   Harigaya, Kenichi ^a   Suzuki, Masato ^a   Nagashima, Takeshi ^a   Hashimoto, Hideyuki ^a   Ishii, Genichiro ^a   Miyazaki, Masaru ^a   Nakajima, Nobuyuki ^a   Mikata, Atsuo ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Comedonecrosis; HER 2; Node negative breast carcinoma; p53; Prognosis

Indexed keywords

PROTEIN P53;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CELL STRUCTURE; CHI SQUARE DISTRIBUTION; COMEDONECROSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUMOR VOLUME;

BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NECROSIS; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0041385558     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2003.01514.x     Document Type: Article

References (22)

1. Arnesson L-G, Smeds S, Fagerberg G, Gröntoft O. Follow-up of two treatment modalities for ductal cancer in situ of the breast. Br J Surg 1989; 76: 672-5.
2. Fisher ER, Sass R, Fisher B, Wickerham L, Paik SM. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS). Cancer 1986; 57: 197-208.
3. Lagios MD. Ductal carcinoma in situ: pathology and treatment. Surg Clin North Am 1990; 70: 853-71.
4. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Anderson JA. Ductal carcinoma in situ of the female breast: short-term results of a prospective nationwide study. Am J Surg Pathol 1992; 16: 1183-96.
5. Solin LJ, Yeh I-T, Kurtz J et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation: correlation of pathologic parameters with outcome of treatment. Cancer 1993; 71: 2532-42.
6. van de Vijver MJ, Peterse JL, Mooi WJ et al. Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988; 319: 1239-45.
7. Gusterson BA, Machin LG, Gullick WJ et al. c-erbB-2 expression in benign and malignant breast disease. Br J Cancer 1988; 58: 453-7.
8. Poller DN, Silverstein MJ, Galea M et al. Ductal carcinoma in situ of the breast; a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol 1994; 7: 257-62.
9. O'Malley FP, Vnencak-Jones CL, Dupont WD, Manning FPS, Page DL p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast: immunohistochemical and sequencing data. Lab Invest 1994; 71: 67-72.
10. Silverstein MJ, Poller DN, Waisman JR et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345: 1154-7.
11. Bobrow LG, Happerfield LC, Gregory WM, Millis RR. Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. J Pathol 1995; 176: 333-41.
12. Steeg PS, Clare SE, Lawrence JA, Zhou Q. Molecular analysis of premalignant and carcinoma in situ lesions of the human breast. Am J Pathol 1996; 149: 733-8.
13. Borg A, Linell F, Idvall I et al. HER2/neu amplification and comedo type breast carcinoma. Lancet 1989; 3: 1268-9.
14. Brower ST, Ahmed S, Tartter PI, Bleiweiss I, Amberson JB. Prognostic variables in invasive breast cancer: contribution of comedo versus non-comedo in situ component. Ann Surg Oncol 1995; 2: 440-44.
15. Goldstein NS, Murphy T. Intraductal carcinoma associated with invasive carcinoma of the breast: a comparison of the two lesions with implications for intraductal carcinoma classification systems. Am J Clin Pathol 1996; 106: 312-18.
16. Lampejo OT, Barnes DM, Smith P, Millis RR. Evaluation of infiltrating ductal carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component. Semin Diagn Pathol 1994; 11: 215-22.
17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
18. Bloom HJG, Richardon WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-77.
19. Consensus conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee. Cancer 1997; 80: 1798-802.
20. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
21. Fisher ER, Redmond C, Fisher B. Histologic grading of breast cancer. Pathol Annu 1980; 15: 239-51.
22. Dalton LW, Page DL, Dupont WD. Histologic grading of breast carcinoma: a reproducibility study. Cancer 1994; 73: 2765-70.